Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. Histologically or cytologically confirmed malignant disease~3. Accept chemotherapy for the first time~4. Patients who will receive high emetogenic cancer chemotherapy (HEC) (cisplatin\>=70mg/m2,adriamycin in combination with cyclophosphamide ,cyclophosphamide\>=1500mg/m2,adriamycin\>60mg/m2,epirubicin\>90mg/m2,dacarbazine，ifosfamide\>=2g/m2) or moderate emetogenic chemotherapy cancer (carboplatin\>=300mg/m2,cyclophosphamide\>=600-1000mg/m2,adriamycin\>50mg/m2)~5. Written informed consent~Exclusion Criteria:~1. Pregnant or breast-feeding~2. Uncontrolled psychosis history~3. Inability or unwillingness to understand or cooperate with study procedures~4. Central nervous system tumors primary or secondary~5. Concurrent abdominal radiotherapy~6. History of uncontrolled diabetes mellitus~7. Patients of prostatic hyperplasia ，paralytic ileus，narrow feet glaucoma.~8. Known cardiac arrhythmia, uncontrolled congestive heart failure ,or acute myocardial infarction with the previous six month~9. Pre-existing nausea or vomiting~10. Inadequate hematological function and abnormal liver and renal function.~11. History of sensitivity to olanzapine~12. Concurrent application of quinolone antibiotic therapy~13. Treatment with another antipsychotic agent such as risperidone,quetiapine, clozapine,phenothiazine,or butyrophenone for 30 days prior to or during the chemotherapy.~14. Cytochrome P450 3A4 substrates within 7 days (terfenadine, cisapride, astemizole, pimozide)~15. Concurrent application of systemic corticosteroids~16. Active infection or gastrointestinal dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olanzapine regimen (Type: EXPERIMENTAL): Olanzapine in combination with aprepitant ,palonosetron and dexamethasone.
- Control regimen (Type: OTHER): Aprepitant in combination with palonosetron and dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).